Amazon Bio Discovery enables scientists to run complex computational workflows through more than 40 AI-specialized foundational models, trained on a wide range of biological datasets. These models generate and evaluate potential drug molecules, alongside AI agents that help scientists to select models, optimize inputs and evaluate candidates according to their research.
Goldman Sachs' Chief Equity Strategist Peter Oppenheimer has called the recent sell-off in U.S. tech stocks a rare 'buying opportunity,' suggesting that the current market conditions may favor investment in this sector.
Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.
We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, stated Shai Novik, Executive Chairman of Enlivex.
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.
RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease.
But he'd been considering an idea for new technology-an autonomous, wind-powered cargo ship. Then, while on paternity leave in 2024, he discovered a free program that helps scientists and engineers launch businesses for the first time. Weeks after finishing the program, called 5050, Cymbalist had launched a startup called Clippership. The company's first ship is being built in the Netherlands this year. Without the accelerator, he says, the company likely wouldn't exist.
We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.
Just one month after raising $11.75 million in a round led by Joe Lonsdale's 8VC, African defensetech Terra Industries announced that it's raised an additional $22 million in funding, led by Lux Capital. Nathan Nwachuku, 22, and Maxwell Maduka, 24, launched Terra Industries in 2024 to design infrastructure and autonomous systems to help African nations monitor and respond to threats.
About 40% of Chinese employees stay in one job for less than two years, according to a Hay Group study. In India, annual turnover of 50% or more is not unusual. That's clearly a problem, not only because constantly recruiting and training people over and over again is expensive, but because it's disruptive. Continuity, let alone growth, can be tough to maintain when half your team is made up of brand-new faces every few months.
EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.
The question many enterprises are asking themselves in 2026 is whether they are transforming their businesses fast enough to see the benefits of new technologies, most notably AI. The answer, according to PwC's 29th Global CEO Survey: Not really - at least, not yet. In fact, the majority of enterprises aren't seeing any real revenue increase or cost reduction as the result of AI deployments; only about one-third have seen any tangible benefits from AI in the last 12 months.
For families living with neurodegenerative disease, the hardest part is not always the diagnosis. It is the slow erosion that follows: memory fading, personality shifting, independence shrinking. It unfolds quietly. First, forgotten appointments. Then repeated questions. Then moments when a familiar face no longer feels familiar. The illness does not isolate itself to one body. It rearranges the lives around it.
The CAFC affirmed as to anticipation but reversed as to obviousness, holding that the Board relied on the wrong legal standard in finding no motivation to combine. The court emphasized that KSR v. Teleflex explicitly eschews such a rigid approach to obviousness, indicating the PTAB failed to properly apply flexible, common-sense reasoning when evaluating whether combining prior art references would have been obvious to one skilled in the art.
The Office de-designated Proppant Express Invests., LLC v. Oren Techs., LLC, IPR2017-01917, Paper 86 (PTAB Feb. 13, 2019); and Adello Biologics LLC v. Amgen Inc., PGR2019-00001, Paper 11 (PTAB Feb. 14, 2019). According to a USPTO email sent Tuesday, both decisions conflict with the decision in Corning Optical Communications RF, LLC v. PPC Broadband Inc., IPR2014-00440, Paper 68 (PTAB Aug. 18, 2015) (precedential).
This week in Other Barks & Bites, IPWatchdog's IP news roundup: the House of Representatives passes drug patent legislation, while antitrust legislation targeting patent-related activities is introduced into the Senate and the Trump administration mandates pricing information for pharmaceutical ads; the Patent Trial and Appeal Board (PTAB) issues a pair of precedential decisions on cases with multiple petitions; the USPTO issues marijuana-related trademark guidelines and a notice on modifying patent term adjustment practices;
Orna is developing a new treatment that uses circular RNA and specialized lipid particles to prompt a patient's own body to produce the cell therapies needed to fight disease. The technology has the potential to "unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options," said Francisco Ramírez-Valle, senior vice president and head of Immunology Research and Early Clinical Development at Eli Lilly, in a statement.
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R. Berkley Corp. ( NYSE: WRB). And public offerings of shares of biotech firms Alumis Inc. ( NASDAQ: ALMS) and Aktis Oncology Inc. ( NASDAQ: AKTS) also brought insiders to the Buy window. Though these were the most prominent insider purchases in the past week, there were a handful of other notable ones as well. Let's take a quick look at these transactions.
Corning Incorporated ( NYSE:GLW) has delivered one of 2026's most impressive rallies, climbing 50.2% year-to-date and 46% over the past month. Corning's 2026 is so good, it's now the 6th top performing stock in the entire S&P 500. The 175-year-old materials science company is riding three converging waves: stellar earnings execution, a massive partnership with Meta, and surging demand for AI data center infrastructure.
